The impressive results of immune checkpoint inhibitors, such as the monoclonal antibodies directed against programmed cell death-1 (PD-1) and its ligand (PD-L1), for the treatment of different solid tumours, have led to evaluate them also in SCLC. The gene discussed is CD274; the disease is small cell lung carcinoma.